Anteris Technologies Global Corp. (AVR)
NASDAQ: AVRHealth CareIndustrial SpecialtiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $486.49M
- EPS (TTM)
- -$1.60
- Dividend yield
- None
- 52-week range
- 3.53 – 11.06
- Day range
- 4.92 – 5.18
- Volume / Avg
- 1.54M / 1.17M
- Beta
- —
- Shares outstanding
- 97.49M
52-week range
AVR stock today
Anteris Technologies Global (AVR) closed at $4.99 on Nov 20, down 1.96% (-$0.10), versus the S&P 500's 3.70% decline. Shares are 54.9% below their 52-week high of $11.06, set on Jul 6, 2026 and 41.4% above the 52-week low of $3.53, near the bottom of the past year's range. AVR is up 0.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 41.8%.
Anteris Technologies Global has posted a net loss over the last twelve months (EPS of -$1.60), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Anteris Technologies Global
Company profileAnteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta.
- Sector
- Health Care
- Industry
- Industrial Specialties
- CEO
- Mr. Wayne Geoffrey Paterson
- Headquarters
- Toowong, QLD
- Employees
- 174
- IPO year
- 2024
- Website
- anteristech.com
Financial highlights
Full financialsIn fiscal 2025, Anteris Technologies Global generated $1.9 million in revenue, down 29.2% from fiscal 2024, the first decline in the 2 years shown. Anteris Technologies Global reported a net loss of $94.1 million, compared with a loss of $76.3 million a year earlier. Gross margin was 70.3% (up from 46.8%) and operating margin -4908.2%.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | $1.91M | $2.70M |
| Growth | -29.23% | — |
| Net income | $-94.14M | $-76.29M |
| EPS (diluted) | $-2.55 | $-3.68 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$13.75+175.55%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.28 vs —
AVR news
All AVR news- Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis PatientsNasdaqAVR, LEN.B
- Anteris’ DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic AnnuliGlobeNewswire
- Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 PatientsGlobeNewswire
- Anteris Technologies Global Corp. GAAP EPS of -$0.28 beats by $0.03, revenue of $0.52M misses by $2.21MSeeking Alpha
- Anteris Technologies Announces Results for the Third Quarter of 2026GlobeNewswire
- Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026GlobeNewswire
- Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026GlobeNewswire
- Anteris Receives German Regulatory Clearance For PARADIGM DurAVR Trial; Stock UpNasdaqAVR, HEI.A
Anteris Technologies Global peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZJYLJIN MEDICAL INTERNATIONAL LTD. Class A | 3.38 | +1.65% | $538.08M | vs AVR |
| PKOHPark-Ohio Holdings Corp. | 40.89 | -4.80% | $591.66M | vs AVR |
| SMTISanara MedTech Inc. | 32.55 | -0.37% | $298.90M | vs AVR |
| MECMayville Engineering Company Inc. | 11.65 | -8.70% | $297.09M | vs AVR |
| ADSEADS-TEC ENERGY PLC | 9.78 | +3.82% | $735.32M | vs AVR |
| ASLEAerSale Corporation | 4.93 | -1.00% | $235.31M | vs AVR |
| OFLXOmega Flex Inc. | 21.15 | -2.08% | $213.49M | vs AVR |
| HDSNHudson Technologies Inc. | 3.91 | -4.17% | $164.57M | vs AVR |
Indexes, lists and sector
Anteris Technologies Global stock FAQ
What is Anteris Technologies Global's stock price today?
AVR last traded at $4.99 as of Nov 20, 4:00 PM EST, down 1.96% on the day. Prices are delayed at least 15 minutes.
Who is Anteris Technologies Global's CEO?
Mr. Wayne Geoffrey Paterson is the chief executive officer of Anteris Technologies Global Corp., which has about 174 employees.
What is the AVR 52-week high?
The 52-week high for AVR is $11.06 and the 52-week low is $3.53. The stock is currently 54.9% below its high.